{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-167078","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.381673+00:00","generated_at":"2026-05-15T05:11:04.281418+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RAP-219 Phase 2a follow-up shows sustained seizure reduction; half-life updated to ~22 days","bullets":["90% median reduction in clinical seizures in weeks 9-12; 59% in weeks 13-16, demonstrating sustained effect after treatment cessation.","Updated half-life of ~22 days (prior 14 days) with plasma concentrations maintaining >75% receptor occupancy through week 12.","Two Phase 3 FOS trials (FOCUS 1 & 2) expected to start Q2 2026; open-label extension ongoing with initial data H2 2026.","RAP-219 well tolerated; 2 mild treatment-related AEs, 3 SAEs unrelated to drug. Phase 2 bipolar mania topline expected H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-167078","json":"https://secwatch.observer/filing/0001193125-26-167078.json","markdown":"https://secwatch.observer/filing/0001193125-26-167078.md","text":"https://secwatch.observer/filing/0001193125-26-167078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526167078/0001193125-26-167078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526167078/rapp-20260421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:11:04.281418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}